Skip to main content
. 2017 Dec 20;27(4):679–690. doi: 10.1093/hmg/ddx434

Figure 4.

Figure 4.

End plate fragmentation is present in nmd muscles regardless of resistance to NMJ denervation. (A) Quantification of percent normal and fragmented end plates in muscles from 8-week wild-type, nmd, and nmd+AAV9-IGHMBP2 treated mice. End plate fragmentation in various selected muscles with differential vulnerability to NMJ denervation encompassing neck, trunk, and distal appendages. AAV9-IGHMPB2 treatment of nmd mice prevents end plate fragmentation in all muscles analyzed. (B) Representative images of immunostained muscle showing presence of end plate fragmentation (arrows) in a muscle resistant to NMJ denervation (cLAL) and prevention of end plate fragmentation by AAV9-IGHMBP2 treatment. Data were analyzed by one-way ANOVA followed by a Bonferroni post hoc test for multiple comparisons. Data are expressed as mean ± SEM. **P < 0.001; ***P < 0.0001. n.s., not significant. n = 3 animals per treatment.